AbbVie's newest HA filler indication targets the décolletage and neck, a high-volume treatment area with limited approved options.
Allergan Aesthetics received FDA approval for SKINVIVE by JUVÉDERM for improvement of neck appearance, expanding the product's labeled indications beyond its original cheek approval. SKINVIVE is a smooth, low-viscosity HA filler designed for superficial placement and gradual collagen stimulation—a positioning distinct from traditional volumizing fillers like JUVÉDERM Ultra or Voluma.
The neck approval is commercially significant: practitioners already inject this area off-label with various HA products, but labeled indication allows for direct marketing, formulary inclusion, and rebate-program eligibility. The décolletage and neck represent a high-volume, recurring-treatment zone—patients often return annually or bi-annually for maintenance, creating predictable revenue.
SKINVIVE approval for neck appearance expands a high-volume, recurring-treatment indication.
This move also signals Allergan's strategy to differentiate SKINVIVE as a dedicated skin-quality and subtle-lift product, competing implicitly against Galderma's Restylane Vital and other superficial-placement fillers. For practices, the approval simplifies compliance documentation and insurance coding.
Source: original report ↗
Free alerts Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo Join the owners who run ahead of the industry. Cancel anytime, one click.
